SINGAPORE: Singaporean biotechnology firm Tychan will begin human clinical trials next week for a potential monoclonal antibody treatment for Covid-19, it said in a statement on Wednesday.
The first phase of the trial will be conducted on healthy volunteers to determine the safety and tolerability of TY027, a monoclonal antibody or immune system protein that specifically targets the virus that causes Covid-19.
Antibodies are generated in the body to fight off infection. Monoclonal antibodies mimic natural antibodies and can be isolated and manufactured in large quantities to treat diseases in patients. – June 10, 2020, Reuters
